vs
Finward Bancorp（FNWD）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Finward Bancorp的季度营收约是Protalix BioTherapeutics, Inc.的1.8倍（$16.5M vs $9.1M），Finward Bancorp净利率更高（12.0% vs -60.3%，领先72.4%），Finward Bancorp同比增速更快（1.1% vs -49.9%），Finward Bancorp自由现金流更多（$9.0M vs $1.6M），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -19.1%）
Finward Bancorp是一家总部位于美国的区域性银行控股公司，主要面向本土运营区域内的个人消费者与中小企业，提供储蓄账户、各类贷款、商业融资及财富管理等零售与商业金融服务。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
FNWD vs PLX — 直观对比
营收规模更大
FNWD
是对方的1.8倍
$9.1M
营收增速更快
FNWD
高出51.0%
-49.9%
净利率更高
FNWD
高出72.4%
-60.3%
自由现金流更多
FNWD
多$7.4M
$1.6M
两年增速更快
PLX
近两年复合增速
-19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.5M | $9.1M |
| 净利润 | $2.0M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 11.0% | -51.1% |
| 净利率 | 12.0% | -60.3% |
| 营收同比 | 1.1% | -49.9% |
| 净利润同比 | -5.6% | -184.8% |
| 每股收益（稀释后） | $0.46 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNWDPLX
| Q4 25 | $16.5M | $9.1M | ||
| Q3 25 | $17.4M | $17.9M | ||
| Q2 25 | $16.6M | $15.7M | ||
| Q1 25 | $15.5M | $10.1M | ||
| Q4 24 | $16.3M | $18.2M | ||
| Q3 24 | $14.9M | $18.0M | ||
| Q2 24 | $14.6M | $13.5M | ||
| Q1 24 | $25.3M | — |
净利润FNWDPLX
| Q4 25 | $2.0M | $-5.5M | ||
| Q3 25 | $3.5M | $2.4M | ||
| Q2 25 | $2.2M | $164.0K | ||
| Q1 25 | $455.0K | $-3.6M | ||
| Q4 24 | $2.1M | $6.5M | ||
| Q3 24 | $606.0K | $3.2M | ||
| Q2 24 | $143.0K | $-2.2M | ||
| Q1 24 | $9.3M | — |
毛利率FNWDPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率FNWDPLX
| Q4 25 | 11.0% | -51.1% | ||
| Q3 25 | 20.5% | 11.9% | ||
| Q2 25 | 12.7% | 7.5% | ||
| Q1 25 | 4.0% | -41.0% | ||
| Q4 24 | 16.3% | 39.6% | ||
| Q3 24 | 2.7% | 22.2% | ||
| Q2 24 | 0.9% | -18.0% | ||
| Q1 24 | 40.6% | — |
净利率FNWDPLX
| Q4 25 | 12.0% | -60.3% | ||
| Q3 25 | 20.1% | 13.2% | ||
| Q2 25 | 12.9% | 1.0% | ||
| Q1 25 | 2.9% | -35.8% | ||
| Q4 24 | 12.9% | 35.6% | ||
| Q3 24 | 4.1% | 18.0% | ||
| Q2 24 | 1.0% | -16.4% | ||
| Q1 24 | 36.7% | — |
每股收益（稀释后）FNWDPLX
| Q4 25 | $0.46 | $-0.06 | ||
| Q3 25 | $0.81 | $0.03 | ||
| Q2 25 | $0.50 | $0.00 | ||
| Q1 25 | $0.11 | $-0.05 | ||
| Q4 24 | $0.50 | $0.10 | ||
| Q3 24 | $0.14 | $0.03 | ||
| Q2 24 | $0.03 | $-0.03 | ||
| Q1 24 | $2.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $174.7M | $48.2M |
| 总资产 | $2.0B | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FNWDPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
股东权益FNWDPLX
| Q4 25 | $174.7M | $48.2M | ||
| Q3 25 | $165.5M | $52.9M | ||
| Q2 25 | $154.3M | $49.9M | ||
| Q1 25 | $151.8M | $45.2M | ||
| Q4 24 | $151.4M | $43.2M | ||
| Q3 24 | $159.6M | $32.4M | ||
| Q2 24 | $148.6M | $28.6M | ||
| Q1 24 | $151.6M | — |
总资产FNWDPLX
| Q4 25 | $2.0B | $82.3M | ||
| Q3 25 | $2.1B | $82.3M | ||
| Q2 25 | $2.1B | $78.5M | ||
| Q1 25 | $2.0B | $73.9M | ||
| Q4 24 | $2.1B | $73.4M | ||
| Q3 24 | $2.1B | $61.6M | ||
| Q2 24 | $2.1B | $91.5M | ||
| Q1 24 | $2.1B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $9.0M | $1.6M |
| 自由现金流率自由现金流/营收 | 54.8% | 17.8% |
| 资本支出强度资本支出/营收 | 5.2% | 4.4% |
| 现金转化率经营现金流/净利润 | 4.99× | — |
| 过去12个月自由现金流最近4个季度 | $10.6M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流FNWDPLX
| Q4 25 | $9.9M | $2.0M | ||
| Q3 25 | $1.2M | $-3.7M | ||
| Q2 25 | $4.8M | $-5.2M | ||
| Q1 25 | $-3.8M | $-5.1M | ||
| Q4 24 | $9.8M | $4.0M | ||
| Q3 24 | $-3.7M | $4.1M | ||
| Q2 24 | $2.8M | $-3.6M | ||
| Q1 24 | $-25.0K | — |
自由现金流FNWDPLX
| Q4 25 | $9.0M | $1.6M | ||
| Q3 25 | $1.0M | $-4.2M | ||
| Q2 25 | $4.5M | $-5.7M | ||
| Q1 25 | $-4.0M | $-5.4M | ||
| Q4 24 | $6.7M | $3.6M | ||
| Q3 24 | $-4.2M | $4.0M | ||
| Q2 24 | $1.1M | $-3.8M | ||
| Q1 24 | $-736.0K | — |
自由现金流率FNWDPLX
| Q4 25 | 54.8% | 17.8% | ||
| Q3 25 | 6.0% | -23.7% | ||
| Q2 25 | 27.0% | -36.2% | ||
| Q1 25 | -25.7% | -53.0% | ||
| Q4 24 | 41.2% | 19.6% | ||
| Q3 24 | -28.5% | 22.4% | ||
| Q2 24 | 7.6% | -28.1% | ||
| Q1 24 | -2.9% | — |
资本支出强度FNWDPLX
| Q4 25 | 5.2% | 4.4% | ||
| Q3 25 | 0.9% | 2.8% | ||
| Q2 25 | 1.7% | 2.8% | ||
| Q1 25 | 1.2% | 3.0% | ||
| Q4 24 | 18.8% | 2.3% | ||
| Q3 24 | 3.4% | 0.5% | ||
| Q2 24 | 11.2% | 1.3% | ||
| Q1 24 | 2.8% | — |
现金转化率FNWDPLX
| Q4 25 | 4.99× | — | ||
| Q3 25 | 0.34× | -1.58× | ||
| Q2 25 | 2.22× | -31.91× | ||
| Q1 25 | -8.37× | — | ||
| Q4 24 | 4.66× | 0.61× | ||
| Q3 24 | -6.15× | 1.27× | ||
| Q2 24 | 19.23× | — | ||
| Q1 24 | -0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNWD
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
